{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:40:27Z","timestamp":1789166427467,"version":"build-2803163510"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The DYNAMIC trial investigated the use of circulating tumor DNA (ctDNA) to guide adjuvant treatment decisions in stage II colon cancer. Despite the DYNAMIC trial\u2019s assertion that a ctDNA-guided approach could minimize the use of adjuvant treatment without compromising recurrence-free survival (RFS), we raised concerns regarding the trial\u2019s methodology and the practical implications of its findings in a Debate article. Here, we expand upon these concerns in a response to a correspondence by the authors of the DYNAMIC trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>We dispute the choice of a large non-inferiority margin in the DYNAMIC trial, simply because an 8.5\u00a0percentage points decrease\u00a0in recurrence-free survival could result in significant harm to patients. We challenge the authors\u2019 comparisons of the DYNAMIC trial outcomes with observational studies. Such comparison is subject to selection bias and changes over time that limit their relevance. The prognostic role of ctDNA do not automatically imply that more treatment in patients with ctDNA positivity would improve outcomes, which we highlight. In real-world settings, we anticipate a potential rise in chemotherapy use due to clinicians utilizing ctDNA alongside existing clinicopathologic factors, rather than using ctDNA as an entire replacement. Lastly, a key concern in DYNAMIC was an 350% higher use of oxaliplatin in the ctDNA arm compared with standard management (9.5% versus 2.7%, respectively), which poses a risk for long-term neuropathy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We look forward improvements in patient selection in the adjuvant setting, but we maintain our reservations about the DYNAMIC trial and the real-life implementation of its results. As an alternative to exploring de-escalation strategies with large margins non-inferiority trials, we propose that superiority trials in stage II patients could be a more effective strategy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-023-03037-9","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:02:14Z","timestamp":1694131334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6936-5783","authenticated-orcid":false,"given":"Timoth\u00e9e","family":"Olivier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"3037_CR1","doi-asserted-by":"publisher","unstructured":"Gibbs P, Hong W, Tie J. Re: Molecular testing to deliver personalized chemotherapy recommendations BMC Med. 2023. https:\/\/doi.org\/10.1186\/s12916-023-03036-w.","DOI":"10.1186\/s12916-023-03036-w"},{"issue":"1","key":"3037_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12916-022-02589-6","volume":"20","author":"T Olivier","year":"2022","unstructured":"Olivier T, Prasad V. Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment. BMC Med. 2022;20(1):392. https:\/\/doi.org\/10.1186\/s12916-022-02589-6.","journal-title":"BMC Med."},{"issue":"2","key":"3037_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.6004\/jnccn.2019.7349","volume":"18","author":"A Haslam","year":"2020","unstructured":"Haslam A, Gill J, Prasad V. An empirical analysis of noninferiority studies in oncology: are they good enough? J Natl Compr Cancer Netw JNCCN. 2020;18(2):161\u20137. https:\/\/doi.org\/10.6004\/jnccn.2019.7349.","journal-title":"J Natl Compr Cancer Netw JNCCN."},{"issue":"14","key":"3037_CR4","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.18.01074","volume":"37","author":"PD Soni","year":"2019","unstructured":"Soni PD, Hartman HE, Dess RT, et al. Comparison of population-based observational studies with randomized trials in oncology. J Clin Oncol. 2019;37(14):1209\u201316. https:\/\/doi.org\/10.1200\/JCO.18.01074.","journal-title":"J Clin Oncol."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03037-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-03037-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03037-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T08:14:08Z","timestamp":1700381648000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-03037-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":4,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3037"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-03037-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"10 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because we used publicly available data, and this is not human subjects research in accordance with 45 CFR \u00a746.102(f), we did not submit this study to an institutional review board or require informed consent procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Vinay Prasad\u2019s disclosures: research funding: Arnold Ventures; royalties: Johns Hopkins Press, Medscape; honoraria: Grand Rounds\/lectures from universities, medical centers, non-profits, and professional societies; consulting: UnitedHealthcare; speaking fees: Evicore; other: Plenary Session podcast has Patreon backers. All other authors have no financial nor non-financial conflicts of interest to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"344"}}